EA008538B1 - Способы и композиции для лечения сердечно-сосудистого заболевания доставкой генов in vivo - Google Patents

Способы и композиции для лечения сердечно-сосудистого заболевания доставкой генов in vivo Download PDF

Info

Publication number
EA008538B1
EA008538B1 EA200200533A EA200200533A EA008538B1 EA 008538 B1 EA008538 B1 EA 008538B1 EA 200200533 A EA200200533 A EA 200200533A EA 200200533 A EA200200533 A EA 200200533A EA 008538 B1 EA008538 B1 EA 008538B1
Authority
EA
Eurasian Patent Office
Prior art keywords
vector
angiogenic
growth factor
gene
peptide
Prior art date
Application number
EA200200533A
Other languages
English (en)
Russian (ru)
Other versions
EA200200533A1 (ru
Inventor
Х. Кирк Хэммонд
Франк Дж. Джиордано
Вольфганг Х. Диллманн
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA200200533A1 publication Critical patent/EA200200533A1/ru
Publication of EA008538B1 publication Critical patent/EA008538B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200200533A 1999-11-05 2000-11-03 Способы и композиции для лечения сердечно-сосудистого заболевания доставкой генов in vivo EA008538B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43515699A 1999-11-05 1999-11-05
US60908000A 2000-06-30 2000-06-30
PCT/US2000/030345 WO2001034208A1 (en) 1999-11-05 2000-11-03 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

Publications (2)

Publication Number Publication Date
EA200200533A1 EA200200533A1 (ru) 2002-12-26
EA008538B1 true EA008538B1 (ru) 2007-06-29

Family

ID=27030448

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200533A EA008538B1 (ru) 1999-11-05 2000-11-03 Способы и композиции для лечения сердечно-сосудистого заболевания доставкой генов in vivo

Country Status (10)

Country Link
EP (1) EP1225921A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003513942A (cg-RX-API-DMAC7.html)
KR (1) KR20020049031A (cg-RX-API-DMAC7.html)
CN (1) CN1433325A (cg-RX-API-DMAC7.html)
AU (1) AU784392B2 (cg-RX-API-DMAC7.html)
CA (1) CA2389524A1 (cg-RX-API-DMAC7.html)
EA (1) EA008538B1 (cg-RX-API-DMAC7.html)
HK (1) HK1048593A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ546670A (cg-RX-API-DMAC7.html)
WO (1) WO2001034208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
AU2008291296B2 (en) * 2007-08-24 2014-02-06 Julius-Maximilians-Universitat Wurzburg Mutant double cyclized receptor peptides inhibiting beta1-adrenoceptor antibodies
CN102046792B (zh) 2008-04-09 2014-12-10 百疗医株式会社 用于提高质粒dna表达的冻干dna制剂
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension
KR101006106B1 (ko) * 2009-06-04 2011-01-07 김현태 전·자기장 차단 전열선
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
JP6562632B2 (ja) * 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
EP2854923B1 (en) 2012-06-05 2019-08-21 Muffin Incorporated Catheter systems and methods useful for cell therapy
CA2926607C (en) 2013-10-22 2018-10-23 Helixmith Co., Ltd Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
US20210393805A1 (en) * 2018-05-16 2021-12-23 University Of Massachusetts Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins
CN112088017B (zh) 2018-07-19 2023-11-21 赫利世弥斯株式会社 用于裸脱氧核糖核酸基因疗法的经冷冻干燥的药剂学组合物
CN114173863A (zh) * 2019-08-07 2022-03-11 西北大学 用于在心脏中基因递送的材料和方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1998032859A1 (en) * 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
WO1998050079A2 (en) * 1997-05-06 1998-11-12 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
WO1999040945A2 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
WO2000038518A1 (en) * 1998-12-28 2000-07-06 Arch Development Corporation Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1998032859A1 (en) * 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
WO1998050079A2 (en) * 1997-05-06 1998-11-12 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
WO1999040945A2 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
WO2000038518A1 (en) * 1998-12-28 2000-07-06 Arch Development Corporation Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GIORDANO F.J. ET AL.: "INTRACORONARY GENE TRANSFER OF FIBROBLAST GROWTH FACTOR-5 INCREASES BLOOD FLOW AND CONTRACTILE FUNCTION IN AN ISCHEMIC REGION OF THE HEART", NATURE MEDICINE, US, NATURE PUBLISHING, CO, vol. 2, no. 5, 1 May 1996 (1996-05-01), pages 534-539, XP000619527, ISSN: 1078-8956, the whole document *
ISNER J.M. ET AL.: "CLINICAL EVIDENCE OF ANGLOGENESIS AFTER ARTERIAL GENE TRANSFER OF PHVEGF165 IN PATIENT WITH ISCHAEMIC LIMB", LANCET THE,GB, LANCET LIMITED. LONDON, vol. 348, 10 August 1996 (1996-08-10), pages 370-374, XP002059360, ISSN: 0140-6736, the whole document *
LEWIS B.S. ET AL.: "ANGIOGENESIS BY GENE THERAPY: A NEW HORIZON FOR MYOCARDIAL REVASCULARIZATION?", CARDIOVASCULAR RESEARCH, XX, XX, vol. 35, no. 3, 1997, pages 490-497, XP000916748, ISSN: 0008-6363, the whole document *
MACK C.A. ET AL.: "SALVAGE ANGIOGENESIS INDUCED BY ADENOVIRUS-MEDIATED GENE TRANSFER OF VASCULAR ENDOTHELIAL GROWTH FACTOR PROTECTS AGAINST ISCHEMIC VASCULAR OCCLUSION," JOURNAL OF VASCULAR SURGERY, C. V. MOSBY CO., ST. LOUIS, MO, US, vol. 27, no. 4, April 1998 (1998-04), pages 699-709, XP000949375, ISSN: 0741-5214, the whole document *
RAJANAYAGAM S. ET AL.: "DELIVERY OF VEGF TO ISCHEMIC TISSUE USING ADENOVIRAL-MODIFIED AUTOLOGOUS ENDOTHELIAL CELLS", CIRCULATION, US, AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 94, no. 8, 15 October 1996 (1996-10-15), page 646, XP002064912, ISSN: 0009-7322, the whole document *

Also Published As

Publication number Publication date
KR20020049031A (ko) 2002-06-24
CA2389524A1 (en) 2001-05-17
WO2001034208A1 (en) 2001-05-17
CN1433325A (zh) 2003-07-30
JP2003513942A (ja) 2003-04-15
AU784392B2 (en) 2006-03-23
NZ546670A (en) 2009-02-28
EP1225921A1 (en) 2002-07-31
EA200200533A1 (ru) 2002-12-26
HK1048593A1 (zh) 2003-04-11
AU1460401A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
US20090082293A1 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
AU706908B2 (en) Gene-transfer-mediated angiogenesis therapy
US6174871B1 (en) Gene therapies for enhancing cardiac function
CA2421584A1 (en) Gene therapy for cardiac arrythmias
AU784392B2 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2289600C (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
EA019099B1 (ru) Способ направленной доставки трансгена в миокард пациента с ишемией миокарда
US20110286931A1 (en) Cardiac arrhythmia treatment methods and biological pacemaker
Lampela Gene therapy of heart failure: aspects of gene delivery and animal modeling
AU706050C (en) Gene transfer-mediated angiogenesis therapy
Merentie Cardiological studies in mice: special emphasis on gene therapy, imaging and ECG findings
AU2006235836A1 (en) Gene transfer-mediated angiogenesis therapy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU